Prospective randomized double-blind trial of 3 versus 6 months of nafarelin therapy for endometriosis associated pelvic pain.

Hornstein MD, Yuzpe AA, Burry KA, Heinrichs LR, Buttram VL Jr, Orwoll ES

Fertility and sterility1 May 1995Cited by 65 (Europe PMC)

PMID7720940DOI10.1016/s0015-0282(16)57530-xPepBankPUB-07720940

Publisher page PubMedAsk about this study

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study4

4 results from studies that gave the peptide. 4 results from people.

01HumanRandomized controlled trialEfficacy outcome
In women with endometriosis, efficacy did not differ significantly between 6 months of nafarelin and 3 months followed by placebo.
In plain wordsIn women with endometriosis, efficacy did not differ between 6 months of nafarelin and 3 months followed by placebo.
Peptide
Nafarelin
Outcome
No significant changeEfficacy by treatment duration
Study
n = 179
Comparator
3 months nafarelin followed by 3 months placebo
Outcome group
Pain · Reproductive and sexual health
Studied dose
Dose not stated · 3 months nafarelin followed by 3 months placebo, or 6 months nafarelin, by groupAs given in this study (human).
Source sentences
Summary
No significant difference in efficacy was noted between the groups.
3 context sentences(design, population, supporting numbers)
Summary · context
One hundred seventy-nine women with pelvic pain and endometriosis.
Summary · context
Patients were assigned randomly to 3 months nafarelin followed by 3 months of placebo (n = 91) or to 6 months nafarelin (n = 88) in a prospective, randomized, double-blind multicenter trial.
Summary · context
Patients were followed for 12 months after cessation of therapy.
Report a problemFND-0772094003
02HumanRandomized controlled trialEfficacy outcome
In women with endometriosis, 26% in each nafarelin duration group underwent retreatment for recurrent symptoms.
In plain wordsIn women with endometriosis, 26% in each nafarelin duration group needed retreatment for recurrent symptoms.
Peptide
Nafarelin
Outcome
No significant changeRetreatment for recurrent symptoms
Study
n = 179
Comparator
3 months nafarelin followed by 3 months placebo
Outcome group
Retreatment · Reproductive and sexual health
Studied dose
Dose not stated · 3 months nafarelin followed by 3 months placebo, or 6 months nafarelin, by groupAs given in this study (human).
Measurements
Patients retreated for recurrent symptoms
26%
each group
Source sentences
Summary
A total of 26% of patients in each group underwent retreatment for recurrent symptoms.
3 context sentences(design, population, supporting numbers)
Summary · context
One hundred seventy-nine women with pelvic pain and endometriosis.
Summary · context
Patients were assigned randomly to 3 months nafarelin followed by 3 months of placebo (n = 91) or to 6 months nafarelin (n = 88) in a prospective, randomized, double-blind multicenter trial.
Summary · context
Patients were followed for 12 months after cessation of therapy.
Report a problemFND-0772094004
03HumanNon-randomized trialEfficacy outcome
In women with endometriosis, pain scores fell significantly from baseline by treatment end in both nafarelin duration groups.
In plain wordsIn women with endometriosis, pain scores fell from baseline in both nafarelin duration groups.
Peptide
Nafarelin
Outcome
DecreasePain at end of treatment
Study
n = 179
Outcome group
Pain · Reproductive and sexual health
Studied dose
Dose not stated · 3 months nafarelin followed by 3 months placebo, or 6 months nafarelin, by groupAs given in this study (human).
Source sentences
Summary
Pain scores dropped significantly by the end of treatment in both groups.
3 context sentences(design, population, supporting numbers)
Summary · context
One hundred seventy-nine women with pelvic pain and endometriosis.
Summary · context
Patients were assigned randomly to 3 months nafarelin followed by 3 months of placebo (n = 91) or to 6 months nafarelin (n = 88) in a prospective, randomized, double-blind multicenter trial.
Summary · context
Patients were followed for 12 months after cessation of therapy.
Report a problemFND-0772094001
04HumanNon-randomized trialEfficacy outcome
In women with endometriosis, pain scores increased during follow-up after nafarelin but remained below baseline in both duration groups.
In plain wordsIn women with endometriosis, pain increased after nafarelin ended but remained below pretreatment levels.
Peptide
Nafarelin
Outcome
MixedPain during follow-up
Study
n = 179
Outcome group
Pain · Reproductive and sexual health
Studied dose
Dose not stated · 3 months nafarelin followed by 3 months placebo, or 6 months nafarelin, by groupAs given in this study (human).
Source sentences
Summary
Symptoms recurred in both groups, and pain scores gradually increased during the follow-up period but always remained below baseline in both groups.
3 context sentences(design, population, supporting numbers)
Summary · context
One hundred seventy-nine women with pelvic pain and endometriosis.
Summary · context
Patients were assigned randomly to 3 months nafarelin followed by 3 months of placebo (n = 91) or to 6 months nafarelin (n = 88) in a prospective, randomized, double-blind multicenter trial.
Summary · context
Patients were followed for 12 months after cessation of therapy.
Report a problemFND-0772094002

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

Version 2Current
28 Oct 2026, 02:03 UTC
Study results updated
Version 1
27 Oct 2026, 16:36 UTC
First added · source update from Europe PMC

Subjects

Terms as the source lists them.

Publication types

MeSH terms

PepBank is a research reference. Talk to a doctor before you use any peptide.